Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies - Additional Information (Details)

v3.22.2
Summary of Significant Accounting Policies - Additional Information (Details)
3 Months Ended 6 Months Ended
Oct. 22, 2019
$ / shares
shares
Jun. 30, 2022
USD ($)
shares
Jun. 30, 2021
USD ($)
Jun. 30, 2022
USD ($)
segment
shares
Jun. 30, 2021
USD ($)
shares
Dec. 31, 2021
shares
Financing Receivable, Impaired [Line Items]            
Tangible asset impairment charges | $   $ 0 $ 0 $ 0 $ 0  
Asset impairment charges | $   0 0 0 0  
Goodwill impairment loss | $   $ 0 0 $ 0 0  
Recapitalization conversion ratio       0.8293    
Common stock, shares issued (in shares) 1 49,213,438   49,213,438   48,627,739
Research and development expense | $   $ 2,355,000 1,116,000 $ 4,420,000 2,426,000  
Advertising expense | $   304,000 296,000 $ 854,000 440,000  
Percentage of largest benefit greater than likelyhood of resolution for tax benefit measurement       50.00%    
Deferred tax assets | $   $ 0 $ 0 $ 0 $ 0  
Effective income tax reconciliation rate       0.00% 0.00%  
Weighted average shares included in computation of earning per share (in shares)       3,993,277 3,819,748  
Number of operating segments | segment       1    
Minimum            
Financing Receivable, Impaired [Line Items]            
Intangible asset useful life       2 years    
Lease terms   4 years   4 years    
Maximum            
Financing Receivable, Impaired [Line Items]            
Intangible asset useful life       10 years    
Lease terms   10 years   10 years    
IPO            
Financing Receivable, Impaired [Line Items]            
Stock issued during period new shares issued (in shares) 13,800,000          
Shares issued (in shares) 1          
Purchase price per share (in USD per share) | $ / shares $ 10.00          
Exercise price of warrants or rights (dollars per share) | $ / shares $ 11.50          
IPO | Private Warrants            
Financing Receivable, Impaired [Line Items]            
Warrants issued (in shares) 1          
Private Placement | Private Warrants            
Financing Receivable, Impaired [Line Items]            
Stock issued during period new shares issued (in shares) 4,110,000          
Exercise price of warrants or rights (dollars per share) | $ / shares $ 1.00          
Conversion of promissory note, warrants issued (in shares) 500,000